Chimeric Therapeutics LimitedASX: CHM

Chimeric Therapeutics: Final Results in Phase 1 Trial of CORE NK Platform

· Issued by Chimeric Therapeutics Limited

Filed with ASX · · 5 pages · English

• Chimeric is advancing development of its CORE NK Platform as a combination therapy in blood cancers and as chimeric antigen receptor (CAR) NK therapies in solid tumors • Webinar to be held at 11am AEDT today. Click here to register. Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce the results of th

Chimeric Therapeutics Limited on 6ix

In the deck

Story so far

Earlier from Chimeric Therapeutics

Later from Chimeric Therapeutics

All Chimeric Therapeutics news releases